Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
“Gastrointestinal tract protection” is not the name of a specific molecule, receptor, or protein but rather refers to a broad set of cellular, molecular, and physiological mechanisms that safeguard the gastrointestinal (GI) tract from physical, chemical, and biological injury[1][2][3][4][6][7]. This phrase therefore does not map to a therapeutic target or molecule as defined by molecular biology or pharmacology conventions. **Gastrointestinal tract protection** encompasses the diverse mechanisms by which the GI tract maintains homeostasis and defends itself from harm. The gut barrier comprises several layers: - The **mechanical barrier** is formed by tightly joined epithelial cells (via tight junctions) that restrict microbial and toxin entry[1][3][4][8]. - The **mucosal barrier** includes the mucus secreted by goblet and mucous cells, which coats the epithelium and neutralizes acid and pathogens[6][3][5]. - **Immune protection** is provided by immune cells in the gut-associated lymphoid tissue (GALT) and secretory IgA[2][4]. - **Antimicrobial peptides and enzymes** are secreted from specialized cells such as Paneth cells and are part of the innate immune defense[4][3]. - The continuous **regeneration** of epithelial cells by stem cells ensures rapid turnover and repair of damage[3][4]. Disruption of these protective mechanisms—such as loss of mucus, breakdown of tight junctions, or impaired cell turnover—can result in ulcers, inflammation, translocation of bacteria (bacterial translocation), infection, and even neoplasia[3][1][5]. “Gastrointestinal tract protection” therefore is not a single molecule or receptor but a description of multiple, coordinated functions and mechanisms involving various cell types, proteins (such as claudins, occludins in tight junctions), and immune factors. For any structured mapping to a target, one should specify a particular molecular component, such as “Mucin 2,” “Tight junction protein claudin-1,” or “Intestinal epithelial cell integrin,” rather than use this system-level functional term.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gastrointestinal tract protection.